Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Brown

Physician Assistant, Surgical Spartanburg, SC Physician Assistant

NPI 1871556126 CMS profile 11055159

225 E Wood St, Spartanburg, SC 29303

Open in the dashboard

General payments

$7,392

158 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Brown of Spartanburg, SC is reported in the CMS Open Payments database as having received $7,392 across 158 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,550 38
2024 General $2,234 41
2023 General $1,309 32
2022 General $714 23
2021 General $585 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Brown
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Jeffrey Brown were reported at $2,550. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Jeffrey Brown Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $585 $111 $36–$285 $132
2022 $714 $126 $44–$350 $149
2023 $1,309 $137 $47–$355 $160
2024 $2,234 $146 $49–$384 $164
2025 $2,550 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Intuitive Surgical, Inc. $2,935 12 payments
  2. Atricure, Inc. $1,641 58 payments
  3. Abbott Laboratories $714 17 payments
  4. Edwards Lifesciences Corporation $573 11 payments
  5. Baxter Healthcare $241 5 payments
  6. Maquet Cardiovascular U.S. Sales, L.L.C. $148 3 payments
  7. Saphena Medical, Inc. $145 2 payments
  8. Abiomed $122 4 payments
  9. Peerless Surgical Inc. $116 3 payments
  10. Silk Road Medical, Inc. $105 5 payments
  11. Other $652 38 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,636 149 payments
  2. Travel and Lodging $2,739 8 payments
  3. Education $17 1 payment
Products named General payments · program years 2021–2025
  1. Da Vinci Surgical System $2,935 12 payments
  2. SYNERGY ABLATION SYSTEM $1,071 34 payments
  3. EPIC $465 10 payments
  4. ATRICLIP LAA EXCLUSION SYSTEM $246 8 payments
  5. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $188 9 payments
  6. COSEAL $161 2 payments
  7. KONECT RESILIA $152 2 payments
  8. Trifecta GT Tissue Heart Valve $146 2 payments
  9. Venapax $145 2 payments
  10. ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2) $143 5 payments
  11. Other $1,866 99 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

238

Median for Physician Assistant: 241

Drug cost

$1,677

Median for Physician Assistant: $4,110

Branded share of claims

12.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Atorvastatin Calcium Generic 40 $667
Amiodarone Hcl Generic 17 $227
Metoprolol Tartrate Generic 67 $198
Clopidogrel Clopidogrel Bisulfate Brand 29 $185
Metoprolol Succinate Generic 12 $109
Potassium Chloride Generic 17 $87
Carvedilol Generic 19 $84
Losartan Potassium Generic 11 $64
Glipizide Generic 12 $38
Furosemide Generic 14 $17

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$5,219

Medicare's payments for the services billed

Medicare patients

35

Average age 75

Services billed

74

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Atrial fibrillation 71%
Heart failure 54%
Arthritis 54%
COPD 43%
Chronic kidney disease 37%
Depression 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

158 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record